471 related articles for article (PubMed ID: 32998516)
1. Endothelial
Theilmann AL; Hawke LG; Hilton LR; Whitford MKM; Cole DV; Mackeil JL; Dunham-Snary KJ; Mewburn J; James PD; Maurice DH; Archer SL; Ormiston ML
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2605-2618. PubMed ID: 32998516
[TBL] [Abstract][Full Text] [Related]
2. Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells.
Szulcek R; Sanchez-Duffhues G; Rol N; Pan X; Tsonaka R; Dickhoff C; Yung LM; Manz XD; Kurakula K; Kiełbasa SM; Mei H; Timens W; Yu PB; Bogaard HJ; Goumans MJ
Angiogenesis; 2020 Nov; 23(4):699-714. PubMed ID: 32813135
[TBL] [Abstract][Full Text] [Related]
3. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Long L; Ormiston ML; Yang X; Southwood M; Gräf S; Machado RD; Mueller M; Kinzel B; Yung LM; Wilkinson JM; Moore SD; Drake KM; Aldred MA; Yu PB; Upton PD; Morrell NW
Nat Med; 2015 Jul; 21(7):777-85. PubMed ID: 26076038
[TBL] [Abstract][Full Text] [Related]
4. Id proteins are critical downstream effectors of BMP signaling in human pulmonary arterial smooth muscle cells.
Yang J; Li X; Li Y; Southwood M; Ye L; Long L; Al-Lamki RS; Morrell NW
Am J Physiol Lung Cell Mol Physiol; 2013 Aug; 305(4):L312-21. PubMed ID: 23771884
[TBL] [Abstract][Full Text] [Related]
5. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
Teichert-Kuliszewska K; Kutryk MJ; Kuliszewski MA; Karoubi G; Courtman DW; Zucco L; Granton J; Stewart DJ
Circ Res; 2006 Feb; 98(2):209-17. PubMed ID: 16357305
[TBL] [Abstract][Full Text] [Related]
6. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
[TBL] [Abstract][Full Text] [Related]
7. PPARγ-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension.
Hennigs JK; Cao A; Li CG; Shi M; Mienert J; Miyagawa K; Körbelin J; Marciano DP; Chen PI; Roughley M; Elliott MV; Harper RL; Bill MA; Chappell J; Moonen JR; Diebold I; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2021 Feb; 128(3):401-418. PubMed ID: 33322916
[TBL] [Abstract][Full Text] [Related]
8. Smooth Muscle Contact Drives Endothelial Regeneration by BMPR2-Notch1-Mediated Metabolic and Epigenetic Changes.
Miyagawa K; Shi M; Chen PI; Hennigs JK; Zhao Z; Wang M; Li CG; Saito T; Taylor S; Sa S; Cao A; Wang L; Snyder MP; Rabinovitch M
Circ Res; 2019 Jan; 124(2):211-224. PubMed ID: 30582451
[TBL] [Abstract][Full Text] [Related]
9. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
[TBL] [Abstract][Full Text] [Related]
10. SEMA3G regulates BMP9 inhibition of VEGF-mediated migration and network formation in pulmonary endothelial cells.
Mirza SL; Upton PD; Hodgson J; Gräf S; Morrell NW; Dunmore BJ
Vascul Pharmacol; 2024 Jun; 155():107381. PubMed ID: 38795838
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension.
Hwangbo C; Lee HW; Kang H; Ju H; Wiley DS; Papangeli I; Han J; Kim JD; Dunworth WP; Hu X; Lee S; El-Hely O; Sofer A; Pak B; Peterson L; Comhair S; Hwang EM; Park JY; Thomas JL; Bautch VL; Erzurum SC; Chun HJ; Jin SW
Circulation; 2017 Jun; 135(23):2288-2298. PubMed ID: 28356442
[TBL] [Abstract][Full Text] [Related]
12. Alk2/ACVR1 and Alk3/BMPR1A Provide Essential Function for Bone Morphogenetic Protein-Induced Retinal Angiogenesis.
Lee HW; Chong DC; Ola R; Dunworth WP; Meadows S; Ka J; Kaartinen VM; Qyang Y; Cleaver O; Bautch VL; Eichmann A; Jin SW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):657-663. PubMed ID: 28232325
[TBL] [Abstract][Full Text] [Related]
13. 4PBA Restores Signaling of a Cysteine-substituted Mutant BMPR2 Receptor Found in Patients with Pulmonary Arterial Hypertension.
Dunmore BJ; Yang X; Crosby A; Moore S; Long L; Huang C; Southwood M; Austin ED; Rana A; Upton PD; Morrell NW
Am J Respir Cell Mol Biol; 2020 Aug; 63(2):160-171. PubMed ID: 32255665
[TBL] [Abstract][Full Text] [Related]
14. Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-β (Transforming Growth Factor-β)-Dependent Pulmonary Arterial Hypertension.
Oliveira SDS; Chen J; Castellon M; Mao M; Raj JU; Comhair S; Erzurum S; Silva CLM; Machado RF; Bonini MG; Minshall RD
Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1191-1202. PubMed ID: 30943774
[TBL] [Abstract][Full Text] [Related]
15. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension.
Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791441
[TBL] [Abstract][Full Text] [Related]
16. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice.
Long L; MacLean MR; Jeffery TK; Morecroft I; Yang X; Rudarakanchana N; Southwood M; James V; Trembath RC; Morrell NW
Circ Res; 2006 Mar; 98(6):818-27. PubMed ID: 16497988
[TBL] [Abstract][Full Text] [Related]
17. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
[TBL] [Abstract][Full Text] [Related]
18. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
Nickel NP; Spiekerkoetter E; Gu M; Li CG; Li H; Kaschwich M; Diebold I; Hennigs JK; Kim KY; Miyagawa K; Wang L; Cao A; Sa S; Jiang X; Stockstill RW; Nicolls MR; Zamanian RT; Bland RD; Rabinovitch M
Am J Respir Crit Care Med; 2015 Jun; 191(11):1273-86. PubMed ID: 25853696
[TBL] [Abstract][Full Text] [Related]
19. Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension.
Tu L; Desroches-Castan A; Mallet C; Guyon L; Cumont A; Phan C; Robert F; Thuillet R; Bordenave J; Sekine A; Huertas A; Ritvos O; Savale L; Feige JJ; Humbert M; Bailly S; Guignabert C
Circ Res; 2019 Mar; 124(6):846-855. PubMed ID: 30636542
[TBL] [Abstract][Full Text] [Related]
20. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
